Last reviewed · How we verify
NCT05922501: ISABELA
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Phase 2 trial testing Isatuximab in Relapsed Cancer in 50 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 31 May 2024 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2030 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Isatuximab (isatuximab) — full drug profile →
- Belantamab mafodotin (BELANTAMAB MAFODOTIN) — full drug profile →
- Pomalidomide — full drug profile →
- Dexamethasone (dexamethasone) — full drug profile →
Conditions studied
- Relapsed Cancer — all drugs for Relapsed Cancer →
- Refractory Multiple Myeloma — all drugs for Refractory Multiple Myeloma →
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Massachusetts General Hospital
Who can join
18 and older, any sex, with Relapsed Cancer or Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent advances in targeted drug delivery systems for multiple myeloma.
Pant A, Laliwala A, Holstein SA, Mohs AM. · · 2024 · cited 9× · PMID 39384153 · DOI 10.1016/j.jconrel.2024.10.003 -
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.
Sorgiovanni I, Del Giudice ML, Galimberti S, Buda G. · · 2025 · cited 1× · PMID 40005960 · DOI 10.3390/ph18020145 -
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.
Chen W, Cai Z, Chim CS, Chng WJ, et al · · 2025 · PMID 40786241 · DOI 10.46989/001c.141401
Verify or expand the search:
- PubMed search for NCT05922501
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Isatuximab
Trials testing the same drug.
- NCT07045909 — Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) · Phase 2 · recruiting
- NCT05862766 — Isatuximab in Lung Transplant Recipients · EARLY_PHASE1 · withdrawn
- NCT06182774 — Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Mu · Phase 3 · recruiting
- NCT06203912 — Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma · Phase 1 · active not recruiting
- NCT05911321 — Isa-Pom-Dex in Elderly/Frail Subjects With RRMM · Phase 2 · active not recruiting
Other recruiting trials for Relapsed Cancer
Currently open trials in the same condition.
- NCT06644183 — Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) · Phase 1, PHASE2 · recruiting
- NCT06634589 — A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap · Phase 1, PHASE2 · recruiting
- NCT05852717 — Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed · Phase 2 · recruiting
- NCT05662397 — A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody · Phase 1, PHASE2 · active not recruiting
- NCT04510636 — Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma · Phase 2 · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05922501 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 14 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05922501.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing